HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $57 price target.
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $67
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $72 to $67.
Bicycle Therapeutics Q4 EPS $(1.01) Beats $(1.06) Estimate, Sales $3.19M Miss $3.88M Estimate
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.06) by 4.72 percent. This is a 60.32 percent decrease over losses of $(0.63) per share
EF Hutton Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target
EF Hutton analyst Tony Butler reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $55 price target.
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $72 Price Target
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.
Bicycle Therapeutics Announces First Patient Dosed In BT8009 Phase II Expansion Cohorts And Provides Program Update
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from
Bicycle Therapeutics Q3 EPS $(0.96) Down From $(0.59) YoY
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.96) per share. This is a 62.71 percent decrease over losses of $(0.59) per share from the same period last year.
Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT8009 Program In Molecular Cancer Therapeutics
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $60 to $45.
Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…